Compounded Semaglutide Efficacy Questioned by Lack of FDA Approval and Varied Formulations
The efficacy and equivalence of compounded semaglutide compared to FDA-approved brand-name products like Ozempic and Wegovy are under scrutiny. While Ozempic and Wegovy are FDA-approved finished products with standardized manufacturing and reviewed evidence, compounded semaglutide does not undergo the same rigorous FDA approval process. Compounded versions can vary significantly in ingredient form (e.g., semaglutide base, sodium, or acetate), concentration, preparation, storage, and administration methods. This variability means that a compounded product, even if it contains the active ingredient, has not been determined by the FDA to be therapeutically equivalent to Ozempic. Patients using compounded semaglutide may experience inconsistent results, and the effectiveness can be influenced by factors such as the prescribed dose, the amount actually injected, and individual physiological responses.